FDA grants fast track designation to CPI-613 for pancreatic cancer

The FDA granted fast track designation to devimistat for the treatment of pancreatic cancer, according to the agent’s manufacturer.

Devimistat (CPI-613, Rafael Pharmaceuticals) targets enzymes in the mitochondria of cancer cells that are involved in cancer cell energy metabolism.

The agent is designed to selectively target the mitochondrial tricarboxylic acid cycle in cancer cells. This process is essential to tumor cell multiplication and survival.

“Receiving fast track designation is a significant milestone in our fight against pancreatic cancer,” Sanjeev Luther, president and CEO of Rafael Pharmaceuticals, said in a company-issued press release. “This designation further stresses the severe unmet need in treatment options for this aggressive and devastating disease.”

The FDA gave Rafael Pharmaceuticals approval to begin pivotal phase 3 trials in pancreatic cancer and acute myeloid leukemia.

“Pancreatic cancer is notoriously challenging to treat and long overdue for a new approach,” Philip A. Philip, MD, PhD, FRCP,professor of oncology at Barbara Ann Karmanos Cancer Institute at Wayne State University and a medical adviser to Rafael Pharmaceuticals, said in the release. “We have remained hopeful throughout our pancreatic cancer trials and, now with fast track designation, our optimism is further fueled. We believe with this designation, cancer metabolism is truly being propelled forward, with devimistat at the helm.”

To Read the Complete Article at Healio, Click Here

Disclaimer: BioPharma Global is not responsible for, and expressly disclaims all liability for, damages of any kind arising out of use, reference to, or reliance on any information contained within the article. Content available through the site may contain links and information to other websites. Links from BioPharma Global to third-party sites do not constitute an endorsement by BioPharma Global of the mentioned parties.

BioPharma Global is a mission-driven corporation, operating like a not-for-profit, dedicated to using our FDA and EMA regulatory expertise and knowledge of various therapeutic areas to help drug developers advance treatments for the disease communities with a high unmet medical need. If you are a drug developer seeking regulatory support for Orphan Drug designation, Fast Track designation, Breakthrough Therapy designation, other FDA/EMA expedited programs, type A, B (pre-IND, EOPs), or C meeting assistance, or IND filings, the BioPharma Global team can help. Contact us today to arrange a 30-minute introductory call.

Stock image by @tatsianama from Depositphotos